DeckTherapeutics appoints new CEO
The biotech entrepreneur Soren Weis Dahl, PhD, MBA today succeeded Suman Lal, MD, PhD, MBA as chief executive of DeckTherapeutics. Dr. Dahl successfully led the development and sale to Rallybio of two orphan drug assets (press release) and will oversee
DeckTherapeutics obtains exclusive license to omega-3 IPR from DSM Nutrition
DeckTherapeutics today announced that the company has signed a letter of intent towards a exclusive intellectual property licensing agreements with the DSM Nutrition. The agreement provides access for DeckTherapeutics to use a proprietary process for manufacturing of novel semi-synthetic omega-3